Ibogaine is routinely listed alongside psilocybin, ayahuasca and ketamine, and the grouping hides the things that matter most. The experience runs for a day rather than an afternoon [1], it carries a cardiac risk the others do not [2], and its evidence base is at an earlier stage than any of them [4].

Why the grouping misleads

The category of psychedelic is partly pharmacological and partly cultural. It gathers compounds that produce altered states, which is a description of an effect rather than of a mechanism, a risk profile or an evidence base.

Grouping ibogaine with the others imports expectations that do not transfer. Someone who has read about psilocybin therapy will picture a session of a few hours with a therapist present, in a setting chosen for comfort.

Almost none of that describes ibogaine. The differences are not matters of degree, and four of them are worth setting out separately.

Duration is the first difference

With ibogaine, intense effects begin one to three hours after the dose and last about four to eight hours, followed by a reflective state of roughly eight to twenty hours [1]. Insomnia often continues for about 72 hours afterwards [1].

Taken together that is twelve to twenty-eight hours of substantial effect, followed by three days of disrupted sleep.

The spread is as notable as the length. A person cannot be told in advance whether their session will run twelve hours or twice that, and part of the variation has a known cause: ibogaine is cleared by an enzyme whose activity varies more than tenfold between people. Someone who clears it slowly holds higher levels for longer, which extends both the experience and the cardiac exposure.

Psilocybin sessions are measured in a single working day, with acute effects of roughly five to seven hours and clinic protocols scheduling the whole visit across a similar span. Ayahuasca ceremonies typically run a few hours. Esketamine is shorter still: the approved product requires patients to be observed for at least two hours after a dose [6].

Duration is not a detail of comfort. It determines how long monitoring must continue, how many staff are needed, and how long a person is unable to leave, make decisions or change their mind.

The cardiac risk is specific to ibogaine

This is the difference that most justifies separating ibogaine from the group.

Ibogaine blocks the heart's hERG potassium channel at concentrations reached during treatment [7], lengthening the QT interval. In a hospital study, a single dose lengthened it by an average of 95 milliseconds and half of the fourteen patients passed 500 milliseconds [2].

The effect also outlasts the drug, typically beyond twenty-four hours and in some cases beyond a week [7].

The other compounds carry their own risks, and they are different in kind. Esketamine's label carries a boxed warning covering sedation, dissociation, respiratory depression, abuse and suicidal thoughts [6], with blood pressure monitoring during the observation period [6]. Ayahuasca preparations combine DMT with monoamine oxidase inhibition, which creates interaction risks with certain medications and foods.

None of those is a channel block that lengthens the cardiac reset for days. Treating ibogaine's risk as a more intense version of a shared psychedelic risk profile is the specific error this comparison exists to prevent.

The content of the experience differs

The published description of ibogaine does not match the popular image of a psychedelic.

The case series describes panoramic recall of past life events, mostly visual, and states that hallucinations were less prominent than the recalled images [1]. In the Dutch cohort, patients reported closed-eye visuals and vivid memories [2].

That is autobiographical review rather than novel visionary content, and the second phase is explicitly described as evaluative and neutral in tone [1].

There is also the physical dimension. All fourteen patients in the Dutch study developed severe transient ataxia and could not walk unaided [2]. Nausea and vomiting are common. The experience is physically incapacitating in a way the shorter compounds generally are not.

If something here speaks to your situation, the next step is a five-minute provider match profile. We read it personally, take your case to vetted providers, and come back with the ones who say yes — or tell you honestly if ibogaine is not the answer.

Find a provider

The mechanisms are not the same

Classic psychedelics such as psilocybin act primarily through serotonin receptor agonism, which gives them a shared pharmacological identity. Ketamine works through a different system again.

Ibogaine does not fit either pattern. It binds at micromolar concentrations to nicotinic acetylcholine receptors, NMDA receptors, kappa and mu opioid receptors, two serotonin receptor types, and the dopamine and serotonin transporters [3].

A review of its cardiac pharmacology calls it a dirty drug, meaning one that acts at many targets rather than selectively [7]. That breadth is why its mechanism remains unresolved after decades of work [3].

The body also converts it into a long-lived metabolite, noribogaine, which has its own activity and its own cardiac effect [3]. The other compounds in the comparison do not present that two-stage pattern in the same way.

The evidence is at a different stage

This difference is the least visible and arguably the most important.

Psilocybin for depressive symptoms has been examined in randomised controlled trials and synthesised in systematic review and meta-analysis [5]. Whatever one concludes from that literature, it is a literature with control groups in it.

Ibogaine has no equivalent. A 2026 review of thirty years of human research concluded that the positive efficacy data comes mostly from uncontrolled studies [4]. The largest published cohorts are case series and open-label observational studies.

That gap is not a judgement about whether ibogaine works. It describes how much has been established, and it means claims about ibogaine and claims about psilocybin rest on different kinds of evidence even when they sound alike.

What an approved treatment looks like

Esketamine is useful as a reference point, because it shows what the regulatory end of this road involves.

It is approved in the United States for treatment-resistant depression in adults [6]. It is available only through a restricted programme, administered in a certified healthcare setting, with the patient observed for at least two hours afterwards and blood pressure reassessed during that period [6].

Those conditions attach to a product that completed controlled trials and carries a boxed warning. They are the shape of supervised access rather than of free availability.

An ibogaine session lasts an order of magnitude longer and involves a substance with a documented QT effect [2]. Whatever framework eventually governs it would reasonably be more demanding, not less, and comparing a weekend abroad with an approved clinic protocol understates that distance.

Where ayahuasca sits

Ayahuasca deserves separate treatment, because it is the comparison most often drawn and the least like ibogaine in structure.

It is a preparation rather than a single compound, combining a plant containing DMT with another that inhibits monoamine oxidase, the enzyme that would otherwise break the DMT down in the gut. The second ingredient is what makes the first active by mouth.

That inhibition is also the source of its characteristic risk. Monoamine oxidase inhibition interacts with certain medications, notably some antidepressants, and with foods containing tyramine. The precaution is a medication and dietary one rather than a cardiac one.

Its usual setting differs too. Ayahuasca is most often taken in a ceremonial group context with a facilitator present throughout, over an evening. Ibogaine protocols that have been published place a person alone on a mat with eye shades, attached to a cardiac monitor, for considerably longer.

The two are sometimes described as interchangeable plant medicines. They share a botanical origin and little else: different active compounds, different durations, different risks and different supervision requirements.

What supervision each requires

The practical requirements follow from the pharmacology, and they diverge sharply.

For psilocybin in trial settings, supervision is largely psychological, with trained personnel present throughout a session of several hours. For esketamine, it is medical and brief: a certified setting and a two-hour observation with blood pressure checks [6].

For ibogaine, it is medical, continuous and long. The protocols that have been published involve baseline EKG and bloodwork, continuous cardiac monitoring through the session, staff trained in advanced cardiac life support, and monitoring extending beyond twenty-four hours because the QT interval can remain prolonged [2].

A person comparing providers across these compounds should expect the requirements to differ, and should treat an ibogaine provider offering the lighter supervision appropriate to a shorter compound as having misunderstood the drug.

Why the comparison matters practically

Someone who has had a positive experience with one of these compounds may approach ibogaine as the next step along a familiar path. The pharmacology does not support that framing.

Previous experience with psilocybin or ayahuasca says nothing about how a person's heart will respond to a hERG channel block, and the screening that matters for ibogaine is cardiac rather than psychological.

The reverse also holds. Someone deterred by ibogaine's risk profile is not thereby making a judgement about the others, which carry different risks and sit at different stages of evidence.

The useful question is never whether psychedelics help, but what this particular compound does, to this particular person, under what supervision.

The grouping has one more practical consequence worth naming. Because these compounds are discussed together, evidence migrates between them in conversation. A trial result for psilocybin becomes, a few retellings later, a general claim about psychedelics, and then support for ibogaine specifically. Each step sounds reasonable and the end point is not supported by anything.

Reading any claim carefully therefore means asking which compound a study actually used. That question resolves a surprising amount of what is written about ibogaine, and the answer is often a different molecule entirely [4].

Where the research goes next

Ibogaine's position in this group would change if controlled trials were run, and the obstacles are practical rather than theoretical.

Blinding is difficult when a compound produces ataxia severe enough to prevent walking [2]. The cardiac profile raises the threshold for ethical approval. And the treatments it is compared against, for depression in particular, already have approved options [6].

Until that work exists, the honest summary is that ibogaine shares a category with these compounds and little else. The evidence overview sets out what the human research has established, and the analogs entry covers attempts to separate the useful effects from the cardiac ones.

Frequently asked questions

Is ibogaine a psychedelic?

It is usually classified as one, and its published description differs from the others: panoramic recall of past life events, mostly visual, with hallucinations less prominent than the recalled images [1].

How long does ibogaine last compared with psilocybin?

Ibogaine's two phases run about four to eight hours and then eight to twenty hours [1], with insomnia often continuing about 72 hours. Psilocybin's acute effects are a matter of hours, and esketamine requires only a two-hour observation period [6].

Is ibogaine riskier than other psychedelics?

Its risk is different in kind. It blocks a cardiac potassium channel and lengthens the QT interval, by an average of 95 milliseconds in one hospital cohort [2], with the effect sometimes persisting beyond a week [7].

Does experience with other psychedelics prepare someone for ibogaine?

Not in the way that matters. The screening that counts for ibogaine is cardiac, and a previous session with another compound says nothing about how a person's heart responds to a hERG channel block [7]. The duration and the physical incapacity also differ substantially [1][2].

Why is there more research on psilocybin?

Psilocybin has been examined in randomised controlled trials and meta-analysis [5], while a 2026 review found ibogaine's positive efficacy data comes mostly from uncontrolled studies [4]. Shorter duration and a lower cardiac risk make controlled trials easier to run.

Safety. Ibogaine prolongs the heart's QT interval and can trigger dangerous arrhythmias. Treatment requires an EKG and bloodwork before dosing, continuous cardiac monitoring during, and medically trained staff present. Ibogaine is not safe to take unsupervised.
Disclaimer: This entry is general information, not medical advice.

References

  1. Alper KR, Lotsof HS, Frenken GMN, Luciano DJ, Bastiaans J. 1999, Am J Addict 8:234-242. pubmed.ncbi.nlm.nih.gov/10506904
  2. Knuijver T, Schellekens A, Belgers M, et al. 2022, Addiction 117(1):118-128. doi:10.1111/add.15448. doi.org/10.1111/add.15448
  3. Marton S, Gonzalez B, Rodriguez-Bottero S, et al. 2019, Front Pharmacol 10:193. frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2019.00193/full
  4. Kervadec E, Bezo A, Serreau R, et al. 2026, J Clin Psychopharmacol. doi:10.1097/jcp.0000000000002197. PMID 42228481. doi.org/10.1097/jcp.0000000000002197
  5. Metaxa AM, Clarke M. 2024, BMJ 385:e078084. Systematic review and meta-analysis of psilocybin for depressive symptoms. pmc.ncbi.nlm.nih.gov/articles/PMC11062320
  6. SPRAVATO (esketamine) nasal spray, US prescribing information, 2025. US Food and Drug Administration. accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf
  7. Koenig X, Hilber K. 2015, Molecules 20(2):2208-2228. doi:10.3390/molecules20022208. PMC4382526. doi.org/10.3390/molecules20022208